Alnylam have some competition

Opinion

... in response to New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam have some competition

JJ says:

August 24, 2012 at 2:30 AM

Gradalis Inc. in Texas have shown a survival advantage x 5 compared to controls in humans in a phase I clinical trial using RNAi in various advanced cancers, with 7 patients still alive after 2 - 3 years. They are currently conducting three phase 2 clinical trials and seeing similar results. These trials use expressed RNAi (shRNA) instead of siRNA, that Alnylam focus on. The expressed RNAi foundation patents are owned by Benitec Biopharma in Australia, who last year combined RNAi in dentritic cells to target arthritis, showing excellent results in mice. Thousands of pre-clinical in-vivo and ex-vivo studies published using shRNA without the delivery problems encountered by siRNA. With a market cap of 1/60th of Alnylam, and equally important IP, they appear very under the radar.

0 0

Reply
- Alnylam have the wherewithal to commercialise their successful products.
  
  fire cracker says:
  
  August 27, 2012 at 11:15 AM
  
  Alnylam have the wherewithal to commercialise their successful products. Neither Gradalis or Benitec Biopharma can match that which makes them both risky propositions until they get Phase lll results.
  
  0 0
  
  Reply

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.